Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathrin Strasser-Weippl

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Cancer|November 15, 2006
Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasiaKathrin Strasser-Weippl, Michael Steurer, Mathias Kees, et al.
Leukemia & Lymphoma|January 7, 2006
Age and hemoglobin level emerge as most important clinical prognostic parameters in patients with osteomyelofibrosis: introduction of a simplified prognostic scoreKathrin Strasser-Weippl, Michael Steurer, Mathias Kees, et al.
NPJ Breast Cancer|April 17, 2026
Comparison of T-DXd-associated pulmonary toxicity in real-world settings and clinical trialsSimon Udovica, Rupert Bartsch, Christian F Singer, et al.
The Lancet. Oncology|May 30, 2014
Breast cancer in ChinaLei Fan, Kathrin Strasser-Weippl, Jun-Jie Li, et al.
Oncoimmunology|November 29, 2023
Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancerMaximilian Marhold, Simon Udovica, Anna Halstead, et al.
Breast Care (Basel, Switzerland)|October 9, 2025
New Perspectives in the Management of Triple-Negative Breast CancerRupert Bartsch, Zsuzsanna Bago-Horvath, Daniel Egle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2018
Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 YearsJulie Lemieux, Michael D Brundage, Wendy R Parulekar, et al.
Wiener Klinische Wochenschrift|September 23, 2022
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 updateGabriel Rinnerthaler, Christian Singer, Edgar Petru, et al.
European Journal of Cancer (Oxford, England : 1990)|February 2, 2016
Identification of early breast cancer patient cohorts who may benefit from lapatinib therapyKathrin Strasser-Weippl, Nora Horick, Ian E Smith, et al.
Breast Cancer Research : BCR|April 19, 2015
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapyKathrin Strasser-Weippl, Nora Horick, Ian E Smith, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Cancer|November 15, 2006
Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasiaKathrin Strasser-Weippl, Michael Steurer, Mathias Kees, et al.
Leukemia & Lymphoma|January 7, 2006
Age and hemoglobin level emerge as most important clinical prognostic parameters in patients with osteomyelofibrosis: introduction of a simplified prognostic scoreKathrin Strasser-Weippl, Michael Steurer, Mathias Kees, et al.
NPJ Breast Cancer|April 17, 2026
Comparison of T-DXd-associated pulmonary toxicity in real-world settings and clinical trialsSimon Udovica, Rupert Bartsch, Christian F Singer, et al.
The Lancet. Oncology|May 30, 2014
Breast cancer in ChinaLei Fan, Kathrin Strasser-Weippl, Jun-Jie Li, et al.
Oncoimmunology|November 29, 2023
Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancerMaximilian Marhold, Simon Udovica, Anna Halstead, et al.
Breast Care (Basel, Switzerland)|October 9, 2025
New Perspectives in the Management of Triple-Negative Breast CancerRupert Bartsch, Zsuzsanna Bago-Horvath, Daniel Egle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2018
Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 YearsJulie Lemieux, Michael D Brundage, Wendy R Parulekar, et al.
Wiener Klinische Wochenschrift|September 23, 2022
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 updateGabriel Rinnerthaler, Christian Singer, Edgar Petru, et al.
European Journal of Cancer (Oxford, England : 1990)|February 2, 2016
Identification of early breast cancer patient cohorts who may benefit from lapatinib therapyKathrin Strasser-Weippl, Nora Horick, Ian E Smith, et al.
Breast Cancer Research : BCR|April 19, 2015
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapyKathrin Strasser-Weippl, Nora Horick, Ian E Smith, et al.
Pageof 4